# Cencora, Inc.: Form 10-Q for the period ended Jun 30, 2018

- Company: [Cencora, Inc.](/companies/cor.md) (CIK 1140859)
- Form: 10-Q
- Filed: 2018-08-02
- Accepted by EDGAR: Aug 2, 2018, 18:19 ET
- Period: 2018-06-30
- Accession: 0001140859-18-000031
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1140859/000114085918000031/a10-qxq32018.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1140859/000114085918000031/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-04-01 to 2018-06-30 | $43.14bn | us-gaap:Revenues |
| Revenue | 9 months, 2017-10-01 to 2018-06-30 | $124.64bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2018-04-01 to 2018-06-30 | $41.93bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2017-10-01 to 2018-06-30 | $121.06bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2018-04-01 to 2018-06-30 | $1.21bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2017-10-01 to 2018-06-30 | $3.58bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2018-04-01 to 2018-06-30 | $626.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2017-10-01 to 2018-06-30 | $1.80bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2018-04-01 to 2018-06-30 | $389.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2017-10-01 to 2018-06-30 | $1.29bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2018-04-01 to 2018-06-30 | $67.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2017-10-01 to 2018-06-30 | −$356.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-04-01 to 2018-06-30 | $275.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2017-10-01 to 2018-06-30 | $1.43bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-04-01 to 2018-06-30 | $1.25 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2017-10-01 to 2018-06-30 | $6.44 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-04-01 to 2018-06-30 | $1.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2017-10-01 to 2018-06-30 | $6.52 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-04-01 to 2018-06-30 | 220,760,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2017-10-01 to 2018-06-30 | 221,297,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2017-10-01 to 2018-06-30 | $746.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2017-10-01 to 2018-06-30 | $248.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2017-10-01 to 2018-06-30 | $251.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2017-10-01 to 2018-06-30 | $300.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-06-30 | $2.39bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-06-30 | $26.40bn | us-gaap:AssetsCurrent |
| Total assets | at 2018-06-30 | $38.31bn | us-gaap:Assets |
| Current liabilities | at 2018-06-30 | $28.10bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2018-06-30 | $4.20bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-06-30 | $30.1m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2018-06-30 | $3.10bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 55,665 characters.

### Overview

The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2017.

We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of our reportable segment presentation.

### Pharmaceutical Distribution Services Segment

The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.

### Other

Other consists of operating segments that focus on global commercialization services and animal health and includes AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI").

ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers.

### Executive Summary

This executive summary provides highlights from the results of operations that follow:

- Revenue increased 11.5% and 9.3% from the prior year quarter and nine month period, respectively, primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;
- Pharmaceutical Distribution Services' gross profit increased 13.8% and 9.6% from the prior year quarter and nine month period, respectively, primarily due to the increase in revenue, the January 2018 consolidation of Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), a leading pharmaceutical wholesaler in Brazil (see Note 2 of the Notes to Consolidated Financial Statements), and the January 2018 acquisition of H.D. Smith, offset in part by a lower contribution from our pharmaceutical compounding operations as it shipped fewer units as production has been voluntarily suspended since December 2017 at our Memphis facility pending execution of certain remedial measures. We have been in active communication with the U.S. Food and Drug Administration ("FDA"), and, on July 19, 2018, PharMEDium informed the FDA of its intent to resume limited production at the Memphis facility and commence commercial distribution in August 2018. We expect production in Memphis to increase gradually over time and to be fully operational in fiscal 2019. Gross profit in Other increased 4.2% and 5.0% from the prior year quarter and nine month period, respectively, primarily due to World Courier and the January 2018 consolidation of the specialty joint venture in Brazil (see Note 2 of the Notes to Consolidated Financial Statements), offset in part by lower gross profit at ABCS, specifically the Lash consulting group. Total gross profit in the current year periods was favorably impacted by an increase in gains from antitrust litigation settlements, and negatively impacted by lower last-in, first-out ("LIFO") credits in comparison to the prior year periods;
- Distribution, selling, and administrative expenses increased 19.2% and 15.0% from the prior year quarter and nine month period, respectively. Pharmaceutical Distribution Services segment increased by 23.7% and 17.0% from the prior year quarter and nine month period, respectively, primarily due to the January 2018 consolidation of Profarma, the January 2018 acquisition of H.D. Smith, and duplicate costs resulting from the implementation of new information technology systems. Distribution, selling, and administrative expenses in Other increased by 9.6% and 10.7% in the current year quarter and nine month period, respectively, primarily to support its revenue growth, the January 2018 consolidation of the specialty joint venture in Brazil, and due to duplicate costs resulting from the implementation of new information technology systems;
- Total segment operating income in the quarter and nine months ended June 30, 2018 was relatively flat compared to the prior year periods. Operating income increased 128.4% and 7.9% in the current year quarter and nine month period, respectively, primarily due to the decrease in employee severance, litigation, and other costs as we incurred significant litigation settlement charges in prior year periods.
- Our effective tax rates were 19.5% and 62.2% in the quarters ended June 30, 2018 and 2017, respectively. Our effective tax rates were (33.4)% and 34.9% in the nine month periods ended June 30, 2018 and 2017, respectively. The effective tax rate in the nine month period ended June 30, 2018 was primarily impacted by the effect of the Tax Cuts and Jobs Act (the "2017 Tax Act"). Our total income tax benefit in the nine month period ended June 30, 2018 of $356.3 million reflects $587.6 million of discrete tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act. We expect that the federal corporate tax rate reduction as a result of the 2017 Tax Act will continue to favorably impact our effective tax rate compared to prior periods through fiscal 2019. The effective tax rates in the quarter and nine months ended June 30, 2017 were negatively impacted by non-deductible legal settlement charges. Our effective tax rates for all interim periods reported herein were favorably impacted by our international businesses in Switzerland and Ireland, which have significantly lower income tax rates, and the benefit from stock option exercises and restricted stock vesting; and
- Net income and earnings per share were significantly higher in the current year quarter and nine month period primarily due to the 2017 Tax Act and non-deductible legal settlement charges that were incurred in the prior year periods.

### Results of Operations

### Revenue

*(dollars in thousands)*

|  | Three months ended June 30, 2018 | 2017 | Change | Nine months ended June 30, 2018 | 2017 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $41,581,866 | $37,255,195 | 11.6% | $119,972,917 | $109,798,844 | 9.3% |
| Other | 1,597,223 | 1,467,536 | 8.8% | 4,736,552 | 4,267,876 | 11.0% |
| Intersegment eliminations | (36,780) | (15,587) |  | (66,970) | (42,909) |  |
| Revenue | $43,142,309 | $38,707,144 | 11.5% | $124,642,499 | $114,023,811 | 9.3% |

We currently expect our revenue in fiscal 2018 to increase between 8% and 11%. Our future revenue growth will continue to be affected by various factors, such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies (including biosimilars), the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs, price increases and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in government rules and regulations.

Revenue increased by 11.5% and 9.3% from the prior year quarter and nine month period, respectively, primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.

The Pharmaceutical Distribution Services segment grew its revenue by 11.6% and 9.3% from the prior year quarter and nine month period, respectively, primarily due to the growth of some of its largest customers, overall market growth, and especially strong oncology product sales. In addition, revenue increased in the current year fiscal periods due to the January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma.

Revenue in Other increased 8.8% and 11.0% from the prior year quarter and nine month period, respectively. The increase from the prior year quarter was primarily due to the January 2018 consolidation of the specialty joint venture in Brazil, ABCS's growth in its Canadian operations, and Word Courier, offset in part by a decrease in revenue at ABCS's Lash consulting group. The increase from the prior year nine month period was primarily due to the January 2018 consolidation of the specialty joint venture in Brazil, increased revenue from MWI, ABCS's growth in its Canadian operations, and World Courier, offset in part by a decrease in revenue at ABCS's Lash consulting group.

A number of our contracts with customers, including group purchasing organizations, are typically subject to expiration each year. We may lose a significant customer if any existing contract with such customer expires without being extended, renewed, or replaced. During the nine months ended June 30, 2018, no significant contracts expired. Over the next twelve months, there are no significant contracts scheduled to expire. Additionally, from time to time, other significant contracts may be renewed prior to their expiration dates. If those contracts are renewed at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.

### Gross Profit

*(dollars in thousands)*

|  | Three months ended June 30, 2018 | 2017 | Change | Nine months ended June 30, 2018 | 2017 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $862,291 | $758,056 | 13.8% | $2,606,008 | $2,378,672 | 9.6% |
| Other | 309,876 | 297,294 | 4.2% | 956,898 | 911,208 | 5.0% |
| Intersegment eliminations | (525) | (198) |  | (761) | (212) |  |
| Gain from antitrust litigation settlements | 35,600 | — |  | 35,938 | 1,395 |  |
| LIFO credit | 16,142 | 24,723 |  | 16,142 | 82,919 |  |
| PharMEDium remediation costs | (12,043) | — |  | (34,549) | — |  |
| Gross profit | $1,211,341 | $1,079,875 | 12.2% | $3,579,676 | $3,373,982 | 6.1% |

22

Gross profit increased 12.2%, or $131.5 million, from the prior year quarter and increased 6.1%, or $205.7 million, from the prior year nine month period. Gross profit in the current year periods was favorably impacted by an increase in gains from antitrust litigation settlements and negatively impacted by lower LIFO credits in comparison to the prior year periods. After recent FDA inspections of our compounding facilities, we voluntarily suspended production activities in December 2017 at our largest compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. The suspension of this production facility negatively impacted gross profit in the current fiscal year periods. We have been in active communication with the FDA, and, on July 19, 2018, PharMEDium informed the FDA of its intent to resume limited production at the Memphis facility and commence commercial distribution in August 2018. We expect production in Memphis to increase gradually over time and to be fully operational in fiscal 2019.

Our cost of goods sold for interim periods includes a LIFO provision that is based on our estimated annual LIFO provision. The annual LIFO provision, which we estimate on a quarterly basis, is affected by manufacturer pricing practices, which may be impacted by market and other external influences, expected changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors may have a material impact to our annual LIFO provision.

Pharmaceutical Distribution Services' gross profit increased 13.8%, or $104.2 million, and 9.6%, or $227.3 million, from the prior year quarter and nine month period, respectively. Gross profit in the current year quarter and nine month period increased primarily due to the increase in revenue, the January 2018 consolidation of Profarma, and the January 2018 acquisition of H.D. Smith, offset in part by a lower contribution from our pharmaceutical compounding operations as it shipped fewer units as we voluntarily suspended production in December 2017 at our Memphis facility. As a percentage of revenue, Pharmaceutical Distribution Services' gross profit margin of 2.07% and 2.17% in the quarter and nine month period ended June 30, 2018, respectively, increased 4 basis points from the prior year quarter and was flat compared to the prior year nine month period. The increase in gross profit margin from the prior year quarter was primarily due to the January 2018 consolidation of Profarma and the January 2018 acquisition of H.D. Smith, offset in part by a lower contribution from our pharmaceutical compounding operations and due to increased sales to our larger customers, which typically have lower gross profit margins.

Gross profit in Other increased 4.2%, or $12.6 million, and 5.0%, or $45.7 million, from the prior year quarter and nine month period, respectively. The increases were primarily due to World Courier and the January 2018 consolidation of the specialty joint venture in Brazil, offset in part by lower gross profit at ABCS, specifically the Lash consulting group. As a percentage of revenue, gross profit margin in Other of 19.40% in the quarter ended June 30, 2018 decreased from 20.26% in the prior year quarter. As a percentage of revenue, gross profit margin in Other of 20.20% in the nine month period ended June 30, 2018 decreased from 21.35% in the prior year period. The declines in gross profit margin in the quarter and nine month period ended June 30, 2018 compared to the prior year periods were primarily due to the decrease in gross profit margin at ABCS, specifically the Lash consulting group.

### Operating Expenses

*(dollars in thousands)*

|  | Three months ended June 30, 2018 | 2017 | Change | Nine months ended June 30, 2018 | 2017 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Distribution, selling, and administrative | $626,548 | $525,463 | 19.2% | $1,802,496 | $1,567,853 | 15.0% |
| Depreciation and amortization | 120,045 | 99,519 | 20.6% | 344,569 | 293,268 | 17.5% |
| Employee severance, litigation, and other | 75,553 | 284,517 |  | 143,023 | 317,517 |  |
| Total operating expenses | $822,146 | $909,499 | (9.6)% | $2,290,088 | $2,178,638 | 5.1% |

Distribution, selling, and administrative expenses increased 19.2%, or $101.1 million, and 15.0%, or $234.6 million, from the prior year quarter and nine month period, respectively, as the Pharmaceutical Distribution Services' segment increased by 23.7% and 17.0% from the prior year quarter and nine month period, respectively, primarily due to the January 2018 consolidation of Profarma, the January 2018 acquisition of H.D. Smith, and duplicate costs resulting from the implementation of new information technology systems. Distribution, selling, and administrative expenses in Other increased by 9.6% and 10.7% in the current year quarter and nine month period, respectively, primarily to support its revenue growth, the January 2018 consolidation of the specialty joint venture in Brazil, and due to duplicate costs resulting from the implementation of new information technology systems. As a percentage of revenue, distribution, selling, and administrative expenses was 1.45% in the current year quarter and nine month period, and represents increases of 9 and 7 basis points compared to the prior year quarter and nine month period, respectively, and is due to the January 2018 consolidation of Profarma and the specialty joint venture in Brazil.

Depreciation expense increased 21.8% and 21.4% from the prior year quarter and nine month period, respectively, due to an increase in the amount of property and equipment placed in service relating to our distribution infrastructure and various technology assets. Amortization expense increased 18.9% and 11.9% from the prior year quarter and nine month period, respectively, primarily due to the amortization of intangible assets originating from our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma.

Employee severance costs in the three and nine months ended June 30, 2018 were $4.8 million and $33.2 million, respectively, and primarily related to position eliminations resulting from our business transformation efforts and restructuring activities related to its consulting business. Litigation costs in the three and nine months ended June 30, 2018 were $39.0 million and $49.5 million, respectively, and primarily related to opioid lawsuits, investigations, and related initiatives. Litigation costs in the three and nine months ended June 30, 2017 were $273.4 million and $289.4 million, respectively, and related to litigation settlements. Other costs in the three months ended June 30, 2018 included $13.0 million related to our business transformation efforts, $9.7 million of other restructuring initiatives, and $9.0 million of acquisition-related deal and integration costs. Other costs in the nine months ended June 30, 2018 included $23.7 million related to our business transformation efforts, $22.0 million of acquisition-related deal and integration costs, and $14.7 million of other restructuring initiatives. Other costs in the three months ended June 30, 2017 included $6.3 million of acquisition-related deal and integration costs, $3.2 million of other restructuring initiatives, and $1.2 million related to our business transformation efforts. Other costs in the nine months ended June 30, 2017 included $15.0 million of acquisition-related deal and integration costs, $11.7 million of other restructuring initiatives, and $1.2 million related to our business transformation efforts.

### Operating Income

*(dollars in thousands)*

|  | Three months ended June 30, 2018 | 2017 | Change | Nine months ended June 30, 2018 | 2017 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $392,652 | $379,976 | 3.3% | $1,269,940 | $1,243,914 | 2.1% |
| Other | 82,296 | 91,338 | (9.9)% | 279,626 | 302,079 | (7.4)% |
| Intersegment eliminations | (525) | (198) |  | (761) | (212) |  |
| Total segment operating income | 474,423 | 471,116 | 0.7% | 1,548,805 | 1,545,781 | 0.2% |
| Gain from antitrust litigation settlements | 35,600 | — |  | 35,938 | 1,395 |  |
| LIFO credit | 16,142 | 24,723 |  | 16,142 | 82,919 |  |
| PharMEDium remediation costs | (15,501) | — |  | (38,007) | — |  |
| Acquisition-related intangibles amortization | (45,916) | (40,946) |  | (130,267) | (117,234) |  |
| Employee severance, litigation, and other | (75,553) | (284,517) |  | (143,023) | (317,517) |  |
| Operating income | $389,195 | $170,376 |  | $1,289,588 | $1,195,344 |  |

Segment operating income is evaluated before gain from antitrust litigation settlements; LIFO credit; PharMEDium remediation costs; acquisition-related intangibles amortization; and employee severance, litigation, and other.

Pharmaceutical Distribution Services' operating income increased 3.3%, or $12.7 million, and 2.1%, or $26.0 million, from the prior year quarter and nine month period, respectively, primarily due to the increase in gross profit, largely offset by an increase in operating expenses. As a percentage of revenue, Pharmaceutical Distribution Services' operating income margin decreased 8 basis points and 7 basis points from the prior year quarter and nine month period, respectively, primarily due to a lower contribution from our pharmaceutical compounding operations as it shipped fewer units as we voluntarily suspended production in December 2017 at our Memphis facility.

Operating income in Other decreased 9.9%, or $9.0 million, and 7.4%, or $22.5 million, from the prior year quarter and nine month period, respectively, primarily due to a decrease in operating income at ABCS, specifically the Lash consulting group, offset in part by the operating income increase at World Courier.

We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the nine months ended June 30, 2018.

Interest expense, net and the respective weighted average interest rates in the quarters ended June 30, 2018 and 2017 were as follows:

*(dollars in thousands)*

|  | 2018 Amount | Weighted Average Interest Rate | 2017 Amount | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $52,845 | 3.64% | $37,017 | 3.07% |
| Interest income | (5,694) | 1.50% | (1,414) | 0.60% |
| Interest expense, net | $47,151 |  | $35,603 |  |

Interest expense, net and the respective weighted average interest rates in the nine month periods ended June 30, 2018 and 2017 were as follows:

*(dollars in thousands)*

|  | 2018 Amount | Weighted Average Interest Rate | 2017 Amount | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $140,212 | 3.55% | $112,889 | 2.90% |
| Interest income | (8,560) | 1.15% | (3,015) | 0.48% |
| Interest expense, net | $131,652 |  | $109,874 |  |

Interest expense, net increased 32.4%, or $11.5 million, from the prior year quarter and 19.8%, or $21.8 million, from the prior year nine month period. The increases were primarily due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma's debt and related interest expense. Average borrowings increased by $680.9 million and $391.3 million in the current year quarter and nine month period, respectively, in comparison to the prior year periods.

In connection with our incremental Brazil investments, we adjusted the carrying values of our previously held equity interests in Profarma and the specialty joint venture to equal their fair values. The adjustments resulted in a loss of $42.3 million, which was comprised of foreign currency translation adjustments from Accumulated Other Comprehensive Loss of $45.9 million, a $12.4 million gain on the remeasurement of Profarma's previously held interest, and an $8.8 million loss on the remeasurement of the specialty joint venture's previously held equity interest (see Note 2 of the Notes to Consolidated Financial Statements).

For the nine month period ended June 30, 2018, we recorded a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019 (see Note 6 of the Notes to Consolidated Financial Statements). The loss on the early retirement of the debt included a $22.3 million prepayment premium and $1.5 million of an unamortized debt discount and unamortized debt issuance costs.

Our effective tax rates were 19.5% and 62.2% in the quarters ended June 30, 2018 and 2017, respectively. Our effective tax rates were (33.4)% and 34.9% in the nine month periods ended June 30, 2018 and 2017, respectively. The effective tax rate in the nine month period ended June 30, 2018 was primarily impacted by the effect of the 2017 Tax Act. Our total income tax benefit in the nine month period ended June 30, 2018 of $356.3 million reflects $587.6 million of discrete tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act. We expect that the federal corporate tax rate reduction as a result of the 2017 Tax Act will continue to favorably impact our effective tax rate compared to prior periods through fiscal 2019. The effective tax rates in the quarter and nine months ended June 30, 2017 were negatively impacted by non-deductible legal settlement charges. Our effective tax rates for all interim periods reported herein were favorably impacted by our international businesses in Switzerland and Ireland, which have significantly lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.

Net income and earnings per share were significantly higher in the current year quarter and nine month period primarily due to the 2017 Tax Act and non-deductible legal settlement charges that were incurred in the prior year periods.

### Liquidity and Capital Resources

The following table illustrates our debt structure as of June 30, 2018, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note, and the overdraft facility:

*(in thousands)*

| Fixed-Rate Debt: | Outstanding Balance | Additional Availability |
| --- | ---: | ---: |
| $500,000, 3.50% senior notes due 2021 | $498,263 | $— |
| $500,000, 3.40% senior notes due 2024 | 497,132 | — |
| $500,000, 3.25% senior notes due 2025 | 495,463 | — |
| $750,000, 3.45% senior notes due 2027 | 742,047 | — |
| $500,000, 4.25% senior notes due 2045 | 494,244 | — |
| $500,000, 4.30% senior notes due 2047 | 492,155 | — |
| Capital lease obligations | 1,434 | — |
| Nonrecourse debt | 69,856 | — |
| Total fixed-rate debt | 3,290,594 | — |
| **Variable-Rate Debt:** |  |  |
| Revolving credit note | — | 75,000 |
| Receivables securitization facility due 2019 | 500,000 | 950,000 |
| Term loans due 2020 | 473,464 | — |
| Multi-currency revolving credit facility due 2021 | — | 1,400,000 |
| Overdraft facility due 2021 (£30,000) | 28,732 | 10,883 |
| Nonrecourse debt | 100,914 | — |
| Total variable-rate debt | 1,103,110 | 2,435,883 |
| Total debt | $4,393,704 | $2,435,883 |

Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, have provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and repurchases of shares of our common stock.

Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund repurchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements.

As of June 30, 2018 and September 30, 2017, our cash and cash equivalents held by foreign subsidiaries were $1,073.8 million and $995.7 million, respectively, and are generally based in U.S. dollar denominated holdings. We expect that our cash and cash equivalents held by foreign subsidiaries may continue to grow. Amounts held outside of the United States are generally used to support non-U.S. liquidity needs, including future acquisitions of non-U.S. entities, although a portion of these amounts are from time to time subject to short-term intercompany loans to U.S. subsidiaries. We continue to evaluate our options on utilizing cash and cash equivalents that are held by our foreign subsidiaries in light of the 2017 Tax Act. In accordance with the 2017 Tax Act (see Note 4 of the Notes to Consolidated Financial Statements), historical foreign earnings and profits are now subject to a one-time transition tax, which we currently estimate to be $310.0 million.

We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, may require the use of our credit facilities to fund short-term capital needs. Our cash balance in the nine months ended June 30, 2018 and 2017 needed to be supplemented by intra-period credit facility borrowings to cover short-term working capital needs. The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the nine months ended June 30, 2018 and 2017 was $1,508.2 million and $626.1 million, respectively. We had $24,493.9 million and $6,780.0 million of cumulative intra-period borrowings that were repaid under our credit facilities during the nine months ended June 30, 2018 and 2017, respectively.

In December 2017, we issued $750 million of 3.45% senior notes due December 15, 2027 (the "2027 Notes") and $500 million of 4.30% senior notes due December 15, 2047 (the "2047 Notes"). The 2027 Notes were sold at 99.76% of the principal amount and have an effective yield of 3.48%. The 2047 Notes were sold at 99.51% of the principal amount and have an effective yield of 4.33%. Interest on the 2027 Notes and the 2047 Notes is payable semi-annually in arrears, commencing on June 15, 2018.

We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D. Smith, which was completed in January 2018.

We have a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which expires in November 2021, with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on our debt rating and ranges from 70 basis points to 110 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of June 30, 2018) and from 0 basis points to 10 basis points over the alternate base rate and Canadian prime rate, as applicable. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on our debt rating, ranging from 5 basis points to 15 basis points, annually, of the total commitment (9 basis points as of June 30, 2018). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of June 30, 2018.

We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program as of June 30, 2018.

We have a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which expires in November 2019. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of June 30, 2018.

We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have a £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short term normal trading cycle fluctuations related to our MWI business.

In February 2015, we entered into a $1.0 billion variable-rate term loan ("February 2015 Term Loan"), which matures in 2020. Through June 30, 2018, we elected to make principal payments, prior to the scheduled repayment dates, of $850 million on the February 2015 Term Loan, and as a result, our next required principal payment is due upon maturity. The February 2015 Term Loan bears interest at a rate equal either to a base rate plus a margin, or LIBOR, plus a margin. The margin is based on our public debt ratings and ranges from 75 basis points to 125 basis points over LIBOR (100 basis points as of June 30, 2018) and 0 basis points to 25 basis points over a base rate. The February 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of June 30, 2018.

In November 2015, we entered into a $1.0 billion variable-rate term loan (the "November 2015 Term Loan"), which matures in 2020. Through June 30, 2018, we made a scheduled principal payment, as well as other principal payments prior to the scheduled repayment dates totaling $675 million on the November 2015 Term Loan, and as a result, our next scheduled principal payment is due upon maturity. The November 2015 Term Loan bears interest at a rate equal either to a base rate, plus a margin, or LIBOR, plus a margin. The margin is based on our public debt ratings and ranges from 75 basis points to 125 basis points over LIBOR (100 basis points as of June 30, 2018) and 0 basis points to 25 basis points over a base rate. The November 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of June 30, 2018.

We consolidated the nonrecourse short-term and long-term debt of Profarma and the specialty joint venture in Brazil in connection with the incremental investments made in January 2018 (see Note 2 and Note 3 of the Notes to Consolidated Financial

Statements). Nonrecourse debt is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.

In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion in shares of our common stock, subject to market conditions. During the nine months ended June 30, 2018, we purchased $325.4 million of our common stock under this program, which included $25.0 million of June 2018 purchases that cash settled in July 2018. As of June 30, 2018, we had $463.5 million of availability remaining under this program.

We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. We had $1.1 billion of variable-rate debt outstanding as of June 30, 2018. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us. There were no such financial instruments in effect as of June 30, 2018.

We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $2,388.9 million in cash and cash equivalents as of June 30, 2018. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every $100 million of cash invested that is in excess of variable-rate debt, a 10 basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.

We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Euro, the U.K. Pound Sterling, the Canadian Dollar, and the Brazilian Real. Revenue from our foreign operations is less than two percent of our consolidated revenue. We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes. As of June 30, 2018, we had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of a C$20.1 million outstanding note.

New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual $100 million Opioid Stewardship Fund (the "Fund") and requires manufacturers, distributors, and importers licensed in NYS to ratably source the Fund. The ratable share of the assessment for each licensee is based upon opioids sold or distributed to or within NYS. The OSA requires licensees to initially report transaction data for the 2017 calendar year by August 1, 2018, which NYS will use to calculate ratable shares of the assessment. Licensees will be notified of their ratable share of the assessment for calendar 2017 by October 15, 2018. The initial payment to NYS is due on January 1, 2019 for opioids sold or distributed during calendar year 2017, and future assessments, beginning with the 2018 calendar year, will be payable quarterly beginning on April 1, 2019. The OSA expires on June 30, 2024. While we have concluded that it is probable that a liability has been incurred, we are unable to reasonably estimate a point estimate or a range of amounts which we may owe under the OSA for the sale or distribution of opioids during the period from January 1, 2017 through June 30, 2018 because the information necessary to determine our share of the assessment is not yet available, and there is significant uncertainty on the application and interpretation of the OSA to our pharmaceutical distribution activities within the state of New York. As a result, no amount has been accrued as of June 30, 2018. We do not expect the OSA will have a material impact to our results of operations or cash flows; however, if other state or local jurisdictions enact similar legislation, such legislation in the aggregate may have a material adverse effect on our results of operations, cash flows, or financial condition.

The following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancelable operating leases and financing obligations, and minimum payments on our other commitments as of June 30, 2018:

| Payments Due by Period (in thousands) | Debt, Including Interest Payments | Operating Leases | Financing Obligations 1 | Other Commitments | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Within 1 year | $338,551 | $92,291 | $27,566 | $83,307 | $541,715 |
| 1-3 years | 1,242,819 | 164,532 | 55,912 | 149,059 | 1,612,322 |
| 4-5 years | 712,657 | 126,120 | 50,614 | 72,366 | 961,757 |
| After 5 years | 3,912,426 | 157,291 | 113,094 | 187,775 | 4,370,586 |
| Total | $6,206,453 | $540,234 | $247,186 | $492,507 | $7,486,380 |
| 1 Represents the portion of future minimum lease payments relating to facility leases where we were determined to be the accounting owner (see Note 1 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended September 30, 2017 for a more detailed description of our accounting for leases). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation. |  |  |  |  |  |

The 2017 Tax Act requires a one-time transition tax to be recognized on historical foreign earnings and profits. We currently estimate that our liability related to the transition tax is approximately $310.0 million as of June 30, 2018, which is payable in installments over an eight-year period commencing in January 2019. The transition tax commitment is included in "Other Commitments" in the above table.

We outsource to IBM Global Services a significant portion of our data center operations. The remaining commitment under our arrangement, which expires in January 2021, is approximately $37.7 million as of June 30, 2018, $15.3 million of which represents our commitment over the next twelve months, and is included in "Other Commitments" in the above table.

Our liability for uncertain tax positions was $254.5 million (including interest and penalties) as of June 30, 2018. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.

During the nine months ended June 30, 2018 and 2017, our operating activities provided cash of $746.0 million and $123.7 million, respectively. Cash provided by operations during the nine months ended June 30, 2018 was principally the result of net income of $1,421.9 million, an increase in accounts payable of $463.9 million, and an increase in income taxes payable of $269.5 million, offset in part by an increase in accounts receivable of $1,107.6 million and negative non-cash items of $241.2 million. The increase in accounts payable was primarily driven by the timing of scheduled payments to suppliers. The increase in income taxes payable was primarily driven by a one-time transition tax on historical foreign earnings and profits through December 31, 2017 in connection with tax reform. The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers. The non-cash items were comprised primarily of a $747.4 million deferred income tax benefit, $233.5 million of depreciation expense, and $149.1 million of amortization expense. The deferred income tax benefit was primarily the result of applying a lower U.S. federal income tax rate to net deferred tax liabilities as of December 31, 2017 in connection with tax reform.

We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon a quarterly average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week in which the month ends.

|  | Three months ended June 30, 2018 | 2017 | Nine months ended June 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Days sales outstanding | 24.6 | 24.2 | 24.4 | 23.5 |
| Days inventory on hand | 28.7 | 30.4 | 30.5 | 30.3 |
| Days payable outstanding | 56.8 | 58.3 | 56.6 | 57.1 |

Our cash flows from operating activities can vary significantly from period to period based on fluctuations in our period end working capital. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. Operating cash flows during the nine months ended June 30, 2018 included $129.0 million of interest payments and $93.2 million of income tax payments, net of refunds. Operating cash flows during the nine months ended June 30, 2017 included $99.0 million of interest payments and $59.4 million of income tax payments, net of refunds.

During the nine months ended June 30, 2017, our operating activities provided cash of $123.7 million. Cash provided by operations during the nine months ended June 30, 2017 was principally the result of an increase in accounts payable of $877.0 million, net income of $709.1 million, non-cash items of $522.8 million, offset in part by an increase in accounts receivable of $1,419.1 million and an increase in merchandise inventories of $829.9 million. The increase in accounts payable was primarily driven by the increase in merchandise inventories and the timing of scheduled payments to our suppliers. The non-cash items were comprised primarily of $225.9 million of deferred income tax expense, $192.9 million of depreciation expense, and $127.4 million of amortization expense. The increase in accounts receivable was the result of our revenue growth and a gradual change in payment terms with our largest customer that occurred between May 2016 and February 2017 as part of a contract amendment that, among other things, extended the term of our relationship with the customer. We increased our merchandise inventories at June 30, 2017 to support the increase in business volume.

Capital expenditures for the nine months ended June 30, 2018 and 2017 were $248.4 million and $371.4 million, respectively. Significant capital expenditures in the nine months ended June 30, 2018 included technology initiatives, including costs related to enhancing and upgrading our enterprise resource planning ("ERP") systems and costs associated with expanding distribution capacity. We currently expect to invest approximately $325 million for capital expenditures during fiscal 2018. Significant capital expenditures in the nine months ended June 30, 2017 included costs associated with expanding distribution capacity and technology initiatives, including costs related to enhancing and upgrading our ERP systems.

In the nine months ended June 30, 2018, we acquired a northeast regional animal health distributor for $70.0 million to expand our animal health business, and we acquired H.D. Smith, the largest independent pharmaceutical wholesaler in the United States, for $815.0 million. In addition, we made incremental investments in Brazil totaling $78.1 million. The cash used on the above investments was offset by $179.6 million of cash consolidated in connection with the Brazil investments (see Note 2 of the Notes to Consolidated Financial Statements).

Net cash provided by financing activities in the nine months ended June 30, 2018 principally included the issuance of $750 million of 3.45% senior notes and $500 million of 4.30% senior notes, offset in part by the early retirement of the $400 million of 4.875% senior notes, $300.4 million in purchases of our common stock, and $251.0 million in cash dividends paid on our common stock. Net cash used in financing activities in the nine months ended June 30, 2017 principally included a $600 million repayment of our 1.15% senior notes, $240.2 million in cash dividends paid on our common stock, and $229.9 million in purchases of our common stock.

In November 2017, our board of directors increased the quarterly cash dividend by 4% from $0.365 per share to $0.380 per share. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remains within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.

### Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in pharmaceutical market growth rates; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; increased public concern over the abuse of opioid medications; prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs, including the reserve recorded in connection with the proceedings with the United States Attorney’s Office for the Eastern District of New York; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; regulatory action in connection with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business; suspension of production of CSPs; failure to realize the expected benefits from our reorganization and other business process initiatives; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of H. D. Smith and PharMEDium, or the inability to capture all of the anticipated synergies related thereto; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and regulations; declining economic conditions in the United States and abroad; financial market volatility and disruption; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; the loss, bankruptcy or insolvency of a major supplier; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the Company’s operations; the impairment of goodwill or other intangible assets (including with respect to foreign operations), resulting in a charge to earnings; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this report, (ii) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2017 and elsewhere in that report and (iii) in other reports filed by the Company pursuant to the Securities Exchange Act.

## Market risk

As filed, 262 characters.

The Company’s most significant market risks are the effects of changing interest rates, foreign currency risk, and changes in the price and volatility of the Company’s common stock. See the discussion under "Liquidity and Capital Resources" in Item 2 on page 26.

## Controls and procedures

As filed, 1,359 characters.

### Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company’s reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

The Company’s Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company’s disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

During the third quarter of fiscal 2018, there was no change in AmerisourceBergen Corporation’s internal control over financial reporting that materially affected, or is reasonably likely to materially affect, internal control over financial reporting.

## Risk factors

As filed, 141 characters.

Our significant business risks are described in Item 1A to Form 10-K for the year ended September 30, 2017 to which reference is made herein.

Filed Aug 2, 2018.
Source: SEC EDGAR, the filing index for accession 0001140859-18-000031. Last ingested by Listed: Nov 15, 2026, 01:23 ET. No prices; not investment advice.
